Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

Novartis EPIC Commitments To sustain our progress, we renewed our EPIC pledge in 2023 to: remain committed to maintain gender representation in management (which seeks to ensure nondiscrimination and ...

The Annual Report 2025, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial ...

Explore opportunities with Novartis below.

MS doesn't always give a clear signal when it's evolving, so it's important to take a moment to reflect and listen to your body. Asking yourself a few questions can give you a clear view of how MS is ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Novartis Pharmaceuticals Corporation (“Novartis”), in cooperation with the U.S. Consumer Product Safety Commission (“CPSC”) and Food and Drug Administration (“FDA”), is voluntarily implementing a CPSC ...

Our Biomedical Research Business Development & Licensing team works with prospective partners to establish collaborations that are mutually beneficial and productive. We remain actively engaged with ...

Novartis has redesigned and scaled our response to the global refugee crisis: going beyond monetary and medicine donations to offer an innovative, inclusive and differentiated approach that is ...

“One of the things I love about working for Novartis is the trust the company has in us. They allow us to work flexibly – so that we can balance our lives, our families and making an impact with our ...